This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Mesothelioma, Non Small Cell Lung Cancer, Malignant Peripheral Nerve Sheath Tumors, Solid Tumor, Pancreatic Adenocarcinoma, Advanced Solid Tumor
This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
-
Mayo Clinic, Phoenix, Arizona, United States, 85054-4502
Sarah Cannon Research Institute (SCRI) - HealthONE Location, Denver, Colorado, United States, 80218-1238
Rocky Mountain Cancer Centers, LLP - Oncology, Lone Tree, Colorado, United States, 80124
Mayo Clinic, Jacksonville, Florida, United States, 32224
Sarah Cannon Research Institute at Florida Cancer Specialists, Orlando, Florida, United States, 32827
Local Institution - 124, Chicago, Illinois, United States, 60637
Dana-Farber Cancer Institute, Brookline, Massachusetts, United States, 02251
Cancer and Hematology Centers of Western Michigan, Norton Shores, Michigan, United States, 49444
Mayo Clinic, Rochester, Minnesota, United States, 55905
Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States, 08901
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
18 Years to
ALL
No
Bristol-Myers Squibb,
Bristol-Myers Squibb, STUDY_DIRECTOR, Bristol-Myers Squibb
2026-04-30